HRMY – Harmony Biosciences Holdings, Inc.
HRMY — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
15.16
Margin Of Safety %
54
Put/Call OI Ratio
1.48
EPS Next Q Diff
0.76
EPS Last/This Y
2.03
EPS This/Next Y
1
Price
27.63
Target Price
42
Analyst Recom
2
Performance Q
-24.84
Upside
243.4%
Beta
0.95
Ticker: HRMY
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-09 | HRMY | 28.6 | 2.13 | 0.23 | 14446 |
| 2026-03-10 | HRMY | 28.74 | 2.13 | 0.05 | 14428 |
| 2026-03-11 | HRMY | 28.79 | 1.95 | 999.99 | 14881 |
| 2026-03-12 | HRMY | 27.79 | 1.96 | 31.00 | 14938 |
| 2026-03-13 | HRMY | 27.79 | 1.96 | 31.00 | 14938 |
| 2026-03-17 | HRMY | 28.37 | 1.95 | 35.00 | 15032 |
| 2026-03-18 | HRMY | 27.82 | 1.95 | 1.63 | 15047 |
| 2026-03-19 | HRMY | 27.79 | 1.96 | 1.19 | 15071 |
| 2026-03-20 | HRMY | 27.73 | 1.95 | 6.66 | 15067 |
| 2026-03-23 | HRMY | 27.55 | 1.65 | 0.13 | 11492 |
| 2026-03-24 | HRMY | 27.09 | 1.53 | 0.55 | 11888 |
| 2026-03-25 | HRMY | 27.58 | 1.52 | 0.30 | 11949 |
| 2026-03-26 | HRMY | 27.56 | 1.52 | 0.15 | 11986 |
| 2026-03-27 | HRMY | 26.53 | 1.51 | 8.00 | 12020 |
| 2026-03-30 | HRMY | 26.88 | 1.51 | 0.00 | 12026 |
| 2026-03-31 | HRMY | 28 | 1.50 | 0.54 | 12050 |
| 2026-04-01 | HRMY | 27.94 | 1.50 | 0.36 | 12060 |
| 2026-04-02 | HRMY | 27.73 | 1.50 | 0.04 | 12096 |
| 2026-04-06 | HRMY | 27.72 | 1.49 | 0.07 | 12138 |
| 2026-04-07 | HRMY | 27.61 | 1.48 | 1.44 | 12157 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-09 | HRMY | 28.57 | -9.9 | 165.1 | 4.79 |
| 2026-03-10 | HRMY | 28.74 | -9.9 | 163.5 | 4.79 |
| 2026-03-11 | HRMY | 28.78 | -9.9 | 160.9 | 4.79 |
| 2026-03-12 | HRMY | 27.78 | -9.9 | 138.5 | 4.79 |
| 2026-03-13 | HRMY | 27.64 | -9.9 | 156.5 | 4.79 |
| 2026-03-17 | HRMY | 28.36 | -9.9 | 171.2 | 4.79 |
| 2026-03-18 | HRMY | 27.82 | -9.9 | 147.7 | 4.79 |
| 2026-03-19 | HRMY | 27.79 | -9.9 | 159.2 | 4.79 |
| 2026-03-20 | HRMY | 27.72 | -9.9 | 4.3 | 4.79 |
| 2026-03-23 | HRMY | 27.60 | -9.9 | 2.6 | 4.79 |
| 2026-03-24 | HRMY | 27.08 | -9.9 | -4.4 | 4.79 |
| 2026-03-25 | HRMY | 27.57 | -9.9 | 2.2 | 4.79 |
| 2026-03-26 | HRMY | 27.42 | -9.9 | 0.1 | 4.79 |
| 2026-03-27 | HRMY | 26.52 | -9.9 | -11.9 | 4.79 |
| 2026-03-30 | HRMY | 26.90 | -9.9 | -6.9 | 4.79 |
| 2026-03-31 | HRMY | 28.00 | -9.9 | 8.0 | 4.79 |
| 2026-04-01 | HRMY | 27.96 | -9.9 | 7.6 | 4.79 |
| 2026-04-02 | HRMY | 27.73 | -9.9 | 4.5 | 4.79 |
| 2026-04-06 | HRMY | 27.71 | -9.9 | 4.2 | 4.79 |
| 2026-04-07 | HRMY | 27.63 | -9.9 | 3.5 | 4.79 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-09 | HRMY | -0.97 | 4.48 | 10.76 |
| 2026-03-10 | HRMY | -0.97 | 4.48 | 10.76 |
| 2026-03-11 | HRMY | -0.97 | 4.48 | 15.81 |
| 2026-03-12 | HRMY | -0.97 | 4.48 | 15.81 |
| 2026-03-13 | HRMY | -0.97 | 4.48 | 15.81 |
| 2026-03-17 | HRMY | -0.97 | 4.54 | 15.81 |
| 2026-03-18 | HRMY | -0.97 | 4.54 | 15.81 |
| 2026-03-19 | HRMY | -0.97 | 4.54 | 15.81 |
| 2026-03-20 | HRMY | -0.97 | 4.54 | 15.81 |
| 2026-03-23 | HRMY | -0.97 | 4.53 | 15.81 |
| 2026-03-24 | HRMY | -0.97 | 4.53 | 15.81 |
| 2026-03-25 | HRMY | -0.97 | 4.53 | 15.16 |
| 2026-03-26 | HRMY | -0.97 | 4.53 | 15.16 |
| 2026-03-27 | HRMY | -0.97 | 4.53 | 15.16 |
| 2026-03-30 | HRMY | -0.97 | 4.68 | 15.16 |
| 2026-03-31 | HRMY | -0.97 | 4.68 | 15.16 |
| 2026-04-01 | HRMY | -0.97 | 4.68 | 15.16 |
| 2026-04-02 | HRMY | -0.97 | 4.68 | 15.16 |
| 2026-04-06 | HRMY | -0.97 | 4.68 | 15.16 |
| 2026-04-07 | HRMY | -0.97 | 4.68 | 15.16 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.38
Avg. EPS Est. Current Quarter
0.93
Avg. EPS Est. Next Quarter
1.14
Insider Transactions
-0.97
Institutional Transactions
4.68
Beta
0.95
Average Sales Estimate Current Quarter
228
Average Sales Estimate Next Quarter
247
Fair Value
42.57
Quality Score
97
Growth Score
97
Sentiment Score
42
Actual DrawDown %
55.5
Max Drawdown 5-Year %
-68.5
Target Price
42
P/E
10.2
Forward P/E
6.54
PEG
0.3
P/S
1.84
P/B
1.83
P/Free Cash Flow
4.59
EPS
2.71
Average EPS Est. Cur. Y
4.79
EPS Next Y. (Est.)
5.79
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
18.27
Relative Volume
0.61
Return on Equity vs Sector %
-9.2
Return on Equity vs Industry %
7.3
EPS 1 7Days Diff
-0.7
EPS 1 30Days Diff
-0.59
EBIT Estimation
3.5
◆
HRMY
Healthcare
$27.62
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
41.1
Range 1M
47.6%
Sup Dist
0.7%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
31.1%
EPS NY
18.9%
52W%
13.6%
Long-Term Value
Quality companies, undervalued
STRONG
🟢 BUY
+343.5% upside
Upside
+343.5%
Quality
97
MoS
54%
Harmony Biosciences Holdings, ISector: Healthcare
Industry: Biotechnology
Employees: 293
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies; CBS105 for the treatment-resistant narcolepsy; and CBS104 for refractory epilepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
HRMY
Latest News
—
Caricamento notizie per HRMY…
stock quote shares HRMY – Harmony Biosciences Holdings, Inc. Stock Price stock today
news today HRMY – Harmony Biosciences Holdings, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch HRMY – Harmony Biosciences Holdings, Inc. yahoo finance google finance
stock history HRMY – Harmony Biosciences Holdings, Inc. invest stock market
stock prices HRMY premarket after hours
ticker HRMY fair value insiders trading